What is the price of nviv stock?
One share of NVIV stock can currently be purchased for approximately $0.50. How much money does InVivo Therapeutics make? InVivo Therapeutics has a market capitalization of $17.26 million.
Is InVivo Therapeutics efficiently growing its dividend?
InVivo Therapeutics does not have a long track record of dividend growth. In the past three months, InVivo Therapeutics insiders have not sold or bought any company stock. Only 0.08% of the stock of InVivo Therapeutics is held by insiders. Only 5.53% of the stock of InVivo Therapeutics is held by institutions.
Will InVivo Therapeutics (nviv) outperform or underperform the S&P 500 over the long term?
MarketBeat's community ratings are surveys of what our community members think about InVivo Therapeutics and other stocks. Vote “Outperform” if you believe NVIV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NVIV will underperform the S&P 500 over the long term. You may vote once every thirty days.
Who is the placement agent for InVivo Therapeutics IPO?
InVivo Therapeutics Holdings Corp. (NVIV) today announced the pricing of a public offering of 7,000,000 shares of its common stock, par value $0.00001 per share, at a price to the public of $0.12 per share. H.C. Wainwright & Co. is acting as exclusive placement agent in connection with the offering.
Is NVIV stock a good buy?
InVivo Therapeutics Holdings Corp (NASDAQ:NVIV) The 1 analysts offering 12-month price forecasts for InVivo Therapeutics Holdings Corp have a median target of 937.50, with a high estimate of 937.50 and a low estimate of 937.50. The median estimate represents a +24,219.07% increase from the last price of 3.86.
Why did NVIV stock drop?
Publisher & Founder. Shares of InVivo Therapeutics $NVIV tanked this morning after the Cambridge, MA-based biotech said it halted enrollment in its lead INSPIRE study after the third patient treated with its spinal cord implant died. InVivo shares plunged more than 30%.
Will NVIV reverse split?
The company anticipates the reverse stock split will become effective at 5:00 p.m. Eastern Time on April 26, 2022, and shares of InVivo Therapeutics common stock will trade on a post-split basis under the company's existing trading symbol, "NVIV," at the market open on April 27, 2022.
What is a 1 for 25 reverse stock split?
PolarityTE (NASDAQ:PTE) has implemented a 1-for-25 reverse stock split of its issued and outstanding common stock, effective May 16, 2022. Each 25 shares of issued and outstanding common stock and equivalents will be converted into one share of common stock.
How do you calculate reverse stock split?
Calculating the effects of a reverse stock split is easy. Simply divide the number of shares you own by the split ratio and multiply the pre-split share price by the same amount. For instance, say a stock trades at $1 per share and the company does a 1-for-10 reverse split.
How has InVivo Therapeutics' stock price performed in 2022?
InVivo Therapeutics' stock was trading at $11.4025 on January 1st, 2022. Since then, NVIV stock has decreased by 59.7% and is now trading at $4.60....
When is InVivo Therapeutics' next earnings date?
InVivo Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022. View our earnings forecast for I...
How were InVivo Therapeutics' earnings last quarter?
InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) posted its earnings results on Tuesday, May, 10th. The biotechnology company reported ($1.94) EPS...
When did InVivo Therapeutics' stock split? How did InVivo Therapeutics' stock split work?
InVivo Therapeutics shares reverse split on the morning of Wednesday, April 27th 2022. The 1-25 reverse split was announced on Wednesday, April 27t...
Who are InVivo Therapeutics' key executives?
InVivo Therapeutics' management team includes the following people: Dr. Richard M. Toselli , Pres, CEO, Chief Medical Officer & Director (Age 64...
Who are some of InVivo Therapeutics' key competitors?
Some companies that are related to InVivo Therapeutics include NeuroMetrix (NURO) , Bluejay Diagnostics (BJDX) , PetVivo (PETV) , Nephros (NEPH...
What other stocks do shareholders of InVivo Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other InVivo Therapeutics investors own include Anavex Life Scie...
What is InVivo Therapeutics' stock symbol?
InVivo Therapeutics trades on the NASDAQ under the ticker symbol "NVIV."
Who are InVivo Therapeutics' major shareholders?
InVivo Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (...
About InVivo Therapeutics
InVivo Therapeutics (NASDAQ:NVIV) Frequently Asked Questions
Invivo Therapeutics Holdings Corp. operates as a research and clinical-stage biotechnology company, which engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries.
News
InVivo Therapeutics' stock was trading at $1.60 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NVIV stock has decreased by 82.1% and is now trading at $0.2858. View which stocks have been most impacted by COVID-19.
Trending Stocks
InVivo Therapeutics Holdings Corp is a research and clinical stage biomaterials and biotechnology company. It focuses on the treatment of spinal cord injury. The company's product pipeline consists of Neuro spinal scaffold and Bioengineered neural trails.
Meridian Bioscience (NASDAQ:VIVO) stock performs better than its underlying earnings growth over last five years
Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these sessions may offer less liquidity and inferior prices. Stock prices may also move more quickly in this environment.
Will Meridian Bioscience (VIVO) Gain on Rising Earnings Estimates?
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
Why Meridian Bioscience's Shares Are Rising Today?
Meridian Bioscience (VIVO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Meridian Bioscience (VIVO) Q1 Earnings and Revenues Surpass Estimates
View more earnings on VIVOSee more from BenzingaDelcath's Chemosat Hepatic Delivery System Shows Overall Response Rate Of 60.5% In Eye Cancer That Spreads To LiverValneva - Pfizer Choose Three-Dose Schedule For Lyme Vaccine Candidate Moving Forward© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
MERIDIAN BIOSCIENCE REPORTS SECOND BEST QUARTER IN COMPANY HISTORY
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 40% and 19.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Hgk Asset Management Inc Buys Fiserv Inc, Duke Energy Corp, Lockheed Martin Corp, Sells ..
Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2021.
Hussman Strategic Advisors, inc Buys Pfizer Inc, Regeneron Pharmaceuticals Inc, Invesco, Sells ..
Jersey City, NJ, based Investment company Hgk Asset Management Inc (Current Portfolio) buys Fiserv Inc, Duke Energy Corp, Lockheed Martin Corp, Healthpeak Properties Inc, Kyndryl Holdings Inc, sells Accenture PLC, Dominion Energy Inc, Welltower Inc, W.W.
About NVIV
Investment company Hussman Strategic Advisors, inc (Current Portfolio) buys Pfizer Inc, Regeneron Pharmaceuticals Inc, Invesco, Dell Technologies Inc, Juniper Networks Inc, sells , Meridian Bioscience Inc, Triton International, Celanese Corp, C.H.
Stats
Invivo Therapeutics Holdings Corp. operates as a research and clinical-stage biotechnology company, which engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries.
Rating
Download the Public app to invest in this stock with any amount of money. Enter your cell phone number below to get started.
Recently Viewed Tickers
What analysts on recommend for this stock, on a scale from 1 (buy) to 5 (sell).
Meridian Bioscience Inc
Visit a quote page and your recently viewed tickers will be displayed here.
When will Meridian Bioscience release its earnings?
Meridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments.
When is Meridian Bioscience earnings call?
Meridian Bioscience is scheduled to release its next quarterly earnings announcement on Friday, August 6th 2021. View our earnings forecast for Meridian Bioscience.
Who bought Meridian Bioscience?
Meridian Bioscience will be holding an earnings conference call on Friday, August 6th at 10:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "3074079".
How much does Meridian Bioscience make?
Company insiders that have bought Meridian Bioscience stock in the last two years include Anthony P Bihl III, Bryan T Baldasare, David Phillips, Felicia Williams, John Mcilwraith, and John P Kenny. View insider buying and selling activity for Meridian Bioscience or or view top insider-buying stocks.
